NCT02158507 2026-01-22
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
University of Alabama at Birmingham
Phase NA Completed
Clinical Trials
12 trialsNCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT01009788 2025-03-14
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT03061188 2024-06-12
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
Northwestern University
Phase 1 Completed
NCT01618357 2024-05-22
Pre-Operative Radiation and Veliparib for Breast Cancer
Indiana University
Phase 1 Completed
NCT04774406 2023-06-06
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
University Hospital, Caen
Completed
NCT04774627 2021-09-23
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
University Hospital, Caen
Completed
NCT01908478 2020-07-15
VelGemRad
Cedars-Sinai Medical Center
Phase 1 Completed
NCT01051596 2019-04-02
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
Georgetown University
Phase 2 Completed
NCT00770471 2018-06-27
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01104259 2017-08-10
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
University of Washington
Phase 1 Completed
NCT01690598 2015-06-10
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Vejle Hospital
Phase 1/2 Completed